Michael D. Mcgoon

Michael D. Mcgoon's AcademicInfluence.com Rankings

Michael D. Mcgoon

Philosophy

#8774

World Rank

#12218

Historical Rank

Logic

#5792

World Rank

#7231

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Michael D. Mcgoon's Degrees

Doctorate Medicine University of Iowa

Why Is Michael D. Mcgoon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael D. Mcgoon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. (1996) (2445)
Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) (2010) (1370)
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. (2006) (1147)
Valvular heart disease associated with fenfluramine-phentermine. (1997) (1130)
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease (2000) (1084)
Primary pulmonary hypertension: natural history and the importance of thrombosis. (1984) (1062)
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. (2010) (1028)
Diagnosis and differential assessment of pulmonary arterial hypertension. (2004) (999)
The natural history of lone atrial fibrillation. A population-based study over three decades. (1987) (967)
Doppler echocardiographic index for assessment of global right ventricular function. (1996) (945)
Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. (1993) (930)
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. (2004) (924)
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 (2008) (915)
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. (2012) (880)
Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. (1990) (730)
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. (1990) (701)
Beraprost therapy for pulmonary arterial hypertension. (2003) (608)
Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin (1994) (566)
Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. (1998) (532)
ACCF/AHA Expert Conseusus Document (2009) (530)
Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. (1985) (504)
Ambrisentan therapy for pulmonary arterial hypertension. (2005) (491)
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. (2012) (429)
[Updated treatment algorithm of pulmonary arterial hypertension]. (2014) (421)
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. (2009) (417)
Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. (2010) (381)
Pulmonary arterial hypertension: epidemiology and registries. (2013) (376)
Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. (2005) (373)
Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. (2006) (371)
Echocardiographic Prediction of Left Ventricular Function after Correction of Mitral Regurgitation: Results and Clinical Implications (1994) (359)
Five-Year outcomes of patients enrolled in the REVEAL Registry. (2015) (320)
Portopulmonary hypertension: Results from a 10‐year screening algorithm (2006) (316)
Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension (1997) (313)
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. (2019) (312)
Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. (2011) (307)
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. (2011) (305)
Survival in Childhood Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (2011) (299)
Updated treatment algorithm of pulmonary arterial hypertension. (2013) (272)
Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension (1999) (255)
Incidence and predictors of cardiac perforation after permanent pacemaker placement. (2005) (251)
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. (2009) (236)
Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension (2003) (229)
Portopulmonary hypertension: a report from the US-based REVEAL Registry. (2012) (222)
Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. (2011) (209)
REVEAL: a contemporary US pulmonary arterial hypertension registry (2012) (198)
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. (2006) (175)
Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. (2012) (160)
Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension (2006) (148)
Design of the REVEAL registry for US patients with pulmonary arterial hypertension. (2008) (145)
Role of serial quantitative assessment of right ventricular function by strain in pulmonary arterial hypertension. (2013) (138)
The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. (2006) (137)
Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. (2011) (137)
Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry (2014) (126)
Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. (2003) (126)
Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. (2013) (110)
Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. (2015) (107)
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. (2009) (106)
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. (2004) (105)
REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. (2011) (103)
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. (1997) (103)
Unexplained pulmonary hypertension in elderly patients. (2007) (100)
Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). (2014) (99)
Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. (2015) (98)
Impaired Left Ventricular Mechanics in Pulmonary Arterial Hypertension: Identification of a Cohort at High Risk (2013) (98)
Breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. (2001) (97)
Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. (1999) (97)
Pulmonary hypertension in patients with interstitial lung diseases. (2007) (97)
Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006. (2007) (95)
Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. (2013) (94)
Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. (1982) (92)
Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. (2009) (89)
Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. (2013) (89)
Temporal trends and drug exposures in pulmonary hypertension: an American experience. (2006) (89)
Relation of tissue displacement and strain to invasively determined right ventricular stroke volume. (2005) (87)
Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. (1984) (84)
Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. (2013) (82)
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. (2002) (80)
The importance of patient perspectives in pulmonary hypertension (2019) (79)
Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage. (2013) (79)
Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol (2009) (79)
Mayo Clinic Practice of Cardiology (1996) (75)
Validation of two predictive models for survival in pulmonary arterial hypertension (2015) (73)
Systemic Collateral and Pulmonary Artery Stenosis in Patients with Congenital Pulmonary Valve Atresia and Ventricular Septal Defect (1977) (71)
[Pulmonary arterial hypertension: epidemiology and registries]. (2014) (70)
Analysis of the Lung Allocation Score Estimation of Risk of Death in Patients With Pulmonary Arterial Hypertension Using Data From the REVEAL Registry (2010) (70)
Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry (2014) (69)
Safety and Efficacy of Epoprostenol in Patients with Severe Congestive Heart Failure (1995) (68)
Vasodilator therapy for primary pulmonary hypertension. (1984) (67)
Pulmonary arterial hypertension: current therapeutic strategies (2007) (66)
Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. (2012) (63)
Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. (1989) (62)
Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. (2013) (59)
The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress (2015) (58)
Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. (2011) (53)
Aortic and mitral valve incompetence: long-term follow-up (10 to 19 years) of patients treated with the Starr-Edwards prosthesis. (1984) (53)
Impaired Left Ventricular Mechanics in Pulmonary Arterial HypertensionClinical Perspective (2013) (51)
Long-term outcome of patients undergoing surgical repair of isolated pulmonary valve stenosis. Follow-up at 20-30 years. (1988) (51)
Obesity drugs and the heart. (1999) (45)
Pulmonary Arterial Hypertension (2006) (45)
The assessment of pulmonary hypertension. (2001) (44)
Perspectives on mitral-valve prolapse. (1999) (43)
Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. (2007) (42)
The clinical use of verapamil. (1982) (41)
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5‐Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry (2018) (37)
ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (2006) (36)
Physician Attitudes toward Palliative Care for Patients with Pulmonary Arterial Hypertension: Results of a Cross-Sectional Survey (2014) (35)
Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. (2008) (32)
Cardiac sarcoidosis: a potentially treatable form of myocarditis. (1985) (30)
Pulmonary hypertension in the setting of acquired systemic arteriovenous fistulas. (2003) (29)
Pulmonary hypertension: diagnosis and management. (2009) (28)
Noninvasive assessment of cardiac risk in insulin-dependent diabetic patients being evaluated for pancreatic transplantation using thallium-201 myocardial perfusion scintigraphy. (1991) (28)
Impact of age on pulmonary artery systolic pressures at rest and with exercise (2016) (28)
Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. (2016) (28)
Chronic aortic regurgitation: indications for operation--1988. (1988) (27)
Diagnostic Dilemmas: Diastolic Heart Failure Causing Pulmonary Hypertension and Pulmonary Hypertension Causing Diastolic Dysfunction (2006) (26)
Permanent cardiac pacing after the Fontan procedure. (1985) (25)
The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension (2018) (25)
Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension. (1983) (23)
Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. (1987) (23)
Syncope in adults with pulmonary arterial hypertension. (2011) (23)
Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. (1995) (22)
Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. (2018) (21)
Extraction of the Telectronics Accufix 330-801 atrial lead: the Mayo Clinic experience. (1996) (19)
Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium. (1998) (19)
Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries (2012) (17)
Long-term endocardial atrial pacing in children with postoperative bradycardia-tachycardia syndrome and limited ventricular access. (1982) (17)
Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. (2018) (16)
Erratum: Beraprost therapy for pulmonary arterial hypertension (Journal of the American College of Cardiology (2003) 41 (2119-2125)) (2003) (16)
Carotid sinus hypersensitivity and syncope. (1984) (15)
Selection of optimal drug therapy for the patient with angina pectoris. (1985) (15)
REVEAL REGISTRY: TREATMENT HISTORY AND TREATMENT AT BASELINE (2007) (14)
Pulmonary Hypertension Care Centers (2014) (13)
The feasibility of utilizing the systolic pre-ejection interval as a determinant of pacing rate. (1989) (13)
Techniques of immunosuppression after cardiac transplantation. (1992) (13)
Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients (2017) (13)
Hemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertension. (2014) (12)
Noninvasive assessment of cardiac risk in insulin-dependent diabetic patients being evaluated for pancreatic transplantation using thallium-201 myocardial perfusion scintigraphy. (1991) (10)
Use of Parenteral Prostanoids at Time of Death in Patients With Pulmonary Arterial Hypertension Enrolled in REVEAL (2011) (9)
Working Group on Cellular and Molecular Mechanisms of Right Heart Failure Right Ventricular Function and Failure : Report of a National Heart , Lung , and Blood (2006) (8)
Portopulmonary hypertension: the next step. (1997) (8)
Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass? (2014) (7)
Medical treatment of pulmonary hypertension. (1995) (7)
Thrombocytopenia independently predicts death in idiopathic PAH (2019) (7)
External validation of the REVEAL risk score calculator for PAH survival: A French pulmonary hypertension network analysis (2012) (7)
Characterization of Prostacyclin‐associated Leg Pain in Patients with Pulmonary Arterial Hypertension (2017) (6)
Clinical trials for pulmonary hypertension in the developing world: pulmonary vascular disease: the global perspective. (2010) (5)
A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH) (2008) (5)
Survival in Pulmonary Arterial Hypertension Parameters in the Prediction of Long-term Integration of Clinical and Hemodynamic (2010) (5)
The late survival after surgical repair of isolated ventricular septal defect vsd (1989) (4)
External validation of the French predictive model to estimate PAH survival: A REVEAL analysis (2012) (4)
Permanent Antitachycardia Pacing for Chronic Atrial Tachyarrhythmias in Postoperative Pediatric Patients (1991) (4)
Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry (2011) (4)
Beta-adrenergic blockers. Choosing among them. (1984) (4)
Chronic aortic regurgitation (1988) (4)
Cardiovascular Procedures: Diagnostic Techniques and Therapeutic Procedures (1987) (3)
Continuous Intravenous Epoprostenol for Pulmonary Arterial Hypertension: Highlighting Practical Issues, Special Considerations (2002) (3)
Long-term continuous prostacyclin treatment improves survival in primary pulmonary hypertension (1993) (3)
228: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension (2009) (3)
Pregnancy and Pulmonary Hypertension (2007) (3)
Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL (2017) (3)
708: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Pulmonary Vascular Disease Associated with Congenital Heart Disease (2009) (3)
Long-term survival, symptomatic status and thromboembolism after starr-edwards prosthesis for isolated aortic or mitral incompetence (1982) (3)
Predicting Medical Disability In Patients With Pulmonary Arterial Hypertension (2011) (3)
Pulmonary Arterial Hypertension (PAH)-Specific Therapy At Time Of Worsening To Functional Class IV In Patients From The REVEAL Registry (2012) (3)
60 Patient and Clinician Perceptions of Palliative Care in Pulmonary Arterial Hypertension (2012) (2)
Ambulatory Hemodynamic Monitoring in Pulmonary Arterial Hypertension (2008) (2)
123: Association between Serial 6-Minute Walk Distance (6MWD) Assessments and the REVEAL Pulmonary Arterial Hypertension (PAH) Risk Score Calculator (2010) (2)
McLaughlin and McGoon Pulmonary Arterial Hypertension (2006) (2)
Noninvasive conversion of a fixed-rate demand pacemaker to activity mode: a method for assessing the clinical effect of rate-responsiveness. (1987) (2)
Articles: Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin (1995) (2)
Diagnostic dilemmas in pulmonary hypertension. (2012) (2)
REVEAL REGISTRY: TWO-YEAR OUTCOMES FROM ENROLLMENT IN NEWLY AND PREVIOUSLY DIAGNOSED PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (2009) (2)
Change in diffusing capacity for carbon monoxide as a predictor of outcomes in connective tissue disease-associated pulmonary arterial hypertension: Analysis from the REVEAL registry (2012) (2)
Ambrisentan Therapy In Patients With Pulmonary Arterial Hypertension Receiving Concomitant Sildenafil Therapy: An Analysis Of The ARIES-3 Study (2010) (2)
Validation Of The French Pulmonary Hypertension Network Equation To Estimate Survival: A REVEAL Analysis (2012) (2)
Use Of The REVEAL Pulmonary Arterial Hypertension (PAH) Risk Score Calculator In Newly Diagnosed Patients (2010) (2)
397: REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated with Congenital Heart Disease (2009) (2)
Four-Year Outcomes of Patients With Pulmonary Arterial Hypertension: Risk, Prognosis, and the Disease Duration Continuum (2011) (1)
317: REVEAL Registry: Does the LAS Score Underestimate the Risk of Death in IPAH (2008) (1)
Hepatic Transaminase Abnormalities in Pulmonary Arterial Hypertension: A Report From the REVEAL Registry (2011) (1)
An integrated approach to the diagnosis of pulmonary hypertension (2011) (1)
REVEAL Registry: Impact of Clinical Worsening on Three-Year Outcomes in Pulmonary Arterial Hypertension (2010) (1)
COMPARISON OF BODY HABITUS IN PULMONARY ARTERIAL HYPERTENSION PATIENTS ENROLLED IN THE REGISTRY TO EVALUATE EARLY AND LONG-TERM PAH DISEASE MANAGEMENT (REVEAL) WITH NORMATIVE VALUES FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES) (2009) (1)
Chapter 7. Pulmonary Hypertension (2007) (1)
Failure ofAtrial Natriuretic Factor to Increase WithVolumeExpansion inAcuteand Chronic Congestive HeartFailure intheDog (1989) (1)
Exercise-Echocardiography-Derived Pulmonary Artery Pressure Slope in Borderline and Mild to Moderate Pulmonary Arterial Hypertension (2008) (1)
REVEAL Registry: Correlation of Right Heart Catheterization and Echocardiogram in Patients with Pulmonary Arterial Hypertension (2009) (1)
Predictors of significant effusion after permanent pacemaker placement (2005) (1)
The Structure of Pulmonary Hypertension Health Care Delivery: Translating Ethical Considerations into Practice (2010) (1)
Ethical Considerations for RCTs in PAH (2009) (1)
Survival in Pulmonary Hypertension Registries: Response (2011) (1)
528: Endothelin-1 and BNP Plasma Levels Predict Survival in Patients with Pulmonary Arterial Hypertension (2009) (1)
The risks of lone atrial fibrillation. (1988) (1)
Acute and short-term hemodynamic and clinical effect of sildenafil in pulmonary arterial hypertension (2003) (1)
The Diagnosis and Treatment of Pulmonary Hypertension (1992) (0)
707: REVEAL Registry: Comparison of Functional Status in Adult PAH Patients with and without Comorbid Medical Conditions (2009) (0)
Coronary Artery Spasm: Pathophysiology, Diagnosis, and Treatment (Basic and Clinical Cardiology, Vol 6) (1986) (0)
Hemodynamics of Pulmonary Hypertension in the Setting of Hereditary Hemorrhagic Telangiectasia (2014) (0)
Disease: The Global Perspective the Developing World : Pulmonary Vascular Clinical Trials for Pulmonary Hypertension in (2010) (0)
To the Editor: (1985) (0)
Syncope, Palpitations, Family History Should Cause Closer Look in Athletes’ Physicals (2004) (0)
Heritable Pulmonary Hypertension With Features Of Pulmonary Venoocclusive Disease (2010) (0)
Recapping Highlights from Pulmonary Hypertension Association Scientific Sessions and Identifying Key Issues Driving Translational Research (2004) (0)
Abstract 9476: Atrial Septostomy in Patients with Pulmonary Arterial Hypertension (2011) (0)
ELECTROCARDIOGRAPHIC CHARACTERISTICS OF PULMONARY HYPERTENSION IN THE SETTING OF HEREDITARY HEMORRHAGIC TELANGIECTASIA (2015) (0)
Rate-responsive pacing using an impedance lead. (1989) (0)
222 Right Heart Catheterization in Patients with Pulmonary Arterial Hypertension: Practice Patterns Observed in the REVEAL Registry (2011) (0)
Hypertensionin Patients With Pulmonary Arterial Parameters in the Prediction of Long-term Integration of Clinical and Hemodynamic (2011) (0)
Characteristics of PAH Patients Treated Initially with Parenteral Prostanoids Differ from Those Treated Initially with Oral Therapy Despite Matching for REVEAL Risk Score (2013) (0)
370 Prognostic Indications of Serial Risk Score Assessments: A REVEAL Analysis (2012) (0)
Characteristics And Four-Year Outcomes Of Patients With Eisenmenger Syndrome In REVEAL (2012) (0)
Long-Term Endocardial Pacing in Children With Postoperative Bradycardia-Tachycardia Syndrome Following the Senning, Mustard and Fontan Operations (1983) (0)
Hypertension : Initial Work-up Critical to Successful Management decongestants (0)
69-year-old woman with ascites, hypoxia, and weight loss. (2013) (0)
Reassessing Patients Over Time : How To Follow Patients on Treatment (2009) (0)
P2-6: Use of permanent pacing leads for temporary pacing (2006) (0)
Survival of valve replacement patients (1977) (0)
Cardiovascular Clinics: Reaffirming an Old Commitment (1984) (0)
Long-term evaluation (11–24 years) of open heart surgery for pulmonary atresia with ventricular septal defect (1982) (0)
Calcium Antagonists and Cardiovascular Disease (1985) (0)
Optical Coherence Tomography in Pulmonary Arteries: A Proof of Concept Study (2014) (0)
Acknowledgment of Reviewers, Volumes 14–18 (2006) (0)
Improvement In Survival In Contemporary Patients With Pulmonary Arterial Hypertension (2012) (0)
Impact of Functional Class Change on Survival in Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From REVEAL (2011) (0)
Syncope in Adults With Pulmonary Arterial Hypertension: Characterization and Prognostic Implications (2010) (0)
Prognostic Significance of Ventricular Interdependence in Right Ventricular Pressure Overload: Reduction in Left Ventricular Systolic Strain Predicts Early Mortality in Pulmonary Arterial Hypertension (2011) (0)
Treatment of Carotid Sinus Hypersensitivity: The authors reply (1985) (0)
Cardiovascular Pharmacology, Michael J. Antonaccio, David H. Frank (Eds.). Raven Press, New York (1984), 606, 2nd ed, with illus, $39.50 (1985) (0)
Childhood pulmonary arterial hypertension: Insights from REVEAL (2011) (0)
Bench to Bedside: Principles and Practice of Epoprostenol Therapy, from Maximizing Benefit to Minimizing Side Effects (2002) (0)
124: Clinical, Echocardiographic, and Prognostic Significance of Pericardial Effusions in Patients with Pulmonary Arterial Hypertension: Outcomes with Pericardiocentesis (2010) (0)
Gender Differences in Pulmonary Arterial Hypertension: Are There Differences Regarding Diagnosis, Treatment, and Outcome Based on the REVEAL Registry?. (2009) (0)
Pacing Therapy: A Guide to Cardiac Pacing for Optimum Hemodynamic Benefit (1984) (0)
Refining Definitions Of Time To Clinical Worsening In Connective Tissue Disease Associated Pulmonary Arterial Hypertension (2010) (0)
THE NATURAL HISTORY OF LONE AF. A POPULATION BASED STUDY OVER THREE DECADES (1987) (0)
844-4 Tissue Doppler strain echocardiography accurately predicts right ventricular systolic function (2004) (0)
Suggested nomenclature code for cardiac pacing leads. (1985) (0)
Cardiac Sarcoidosis: The authors reply (1986) (0)
123: REVEAL Registry: Prevalence, Demographics and Outcomes in Patients with Pulmonary Arterial Hypertension (PAH) Characterized by Higher Left Sided Pressures (2009) (0)
Pulmonary Hypertension, Normal Ejection Fraction and Elevated Pulmonary Capillary Wedge Pressure: Idiopathic Pulmonary Arterial Hypertension or Diastolic Heart Failure? (2004) (0)
CLINICAL AND HEMODYNAMIC PREDICTORS OF SURVIVAL: A SINGLE CENTER STUDY OF 657 PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (2008) (0)
Unexplained pulmonary hypertension in elderly patients. Editorial (2007) (0)
Message from the Board Chair (2006) (0)
Home Oxygen Use Characteristics and Outcomes in Patients With PAH: Data From the Reveal Registry (2016) (0)
256: REVEAL Registry: Implications of Functional Class and Hemodynamics on Outcome in Patients with PAH (2009) (0)
Acknowledgment of Reviewers For Bumc Proceedings, Volumes 15–19 (2007) (0)
Utility of neurohumoral profiles in pulmonary hypertension: clinical and hemodynamic correlations (2003) (0)
Agreement For Functional Class Assignment Among Pulmonary Hypertension Experts Using A Standardized Activities Questionnaire (2010) (0)
HIV-APAH Compared To IPAH: Baseline Characteristics And 2 Year Outcomes From The REVEAL Registry (2010) (0)
PHA Scientific Sessions Break New Ground, Providing Timely, Focused Venue for Current Research (2004) (0)
Erratum: Syncope in adults with pulmonary arterial hypertension (Journal of the American College of Cardiology (2011) 59 (863-867)) (2012) (0)
Left Atrial Volume as an Indicator of Left Heart Disease in Patients with Pulmonary Hypertension (2007) (0)
Abstract 15999: Electrocardiographic Changes Associated With Prognosis in Pulmonary Arterial Hypertension (2011) (0)

This paper list is powered by the following services:

Michael D. Mcgoon's Academic­Influence.com Rankings

Michael D. Mcgoon's Degrees

Why Is Michael D. Mcgoon Influential?

Michael D. Mcgoon's Published Works

Published Works

Michael D. Mcgoon's AcademicInfluence.com Rankings